About   |  Speaker   |  Programme   |  Registration   |  Sponsoring

 


Regenerative Medicine - An Industry Perspective

 

Novel therapeutic approaches in Regenerative Medicine aiming to replace or regenerate diseased tissue have vast potential to tackle unmet patient needs. 

Progress in this field is naturally is being born out of research by academia. The impact of commercial development in this sector is yet to be observed on a grand scale, mainly due to the nature of the discipline still very much in the R&D phase. 

 

Top left - Samantha Paulsen a graduate student in the Jordan Miller lab at Rice University displays a plate on which 3D printed silicone templates have been mounted. In this picture the hollow moulds have been injected with a red dye to better show the pattern of small vessels inside [1]. Credit: Jeff Fitlow/Rice University.

Top Right - 3D printed networks  Endothelial cells, the building blocks of capillaries, veins and arteries (red) line the walls of Miller’s 3D–printed vascular structures [2]. Credit [Jordan Miller/The Scientist]. 

Bottom Left - At the Wake Forest Institute for Regenerative Medicine in Winston-Salem, NC, scientists use a specifically-modified 3D printer to build scaffolding for biomaterials that may one day be used to create organs, tissues and bones for human transplant. Credit: NJTV.

Bottom Right - Hyun-Wook Kang, a postdoctoral fellow at Wake Forest Institute uses a 3D printer that is making a kidney prototype with cells and scaffold biomaterials [1]. Credit: Wake Forest Institute of Regenerative Medicine.

 

 

 

WHAT CAN WE EXPECT OF THE PHARMA INDUSTRY IN TERMS OF MAKING STRONG HEADWAY IN R&D WITHIN REGENERATIVE MEDICINE?

According to current estimates, with over 700 companies worldwide and an equal number of clinical trials underway, the global Regenerative Medicine market is worth approximately $20 billion and is expected to grow at an impressive compound annual growth rate of 20% by the 2020s [3-5].

A key growth driver for this market is the increased focus on cell therapy products, which owes to the rise in demand, increased investments from pharmaceutical and biotechnology companies, and government initiatives [6]. However, some of the persistent challenges that hamper market growth is a strict regulatory framework, the cost of manufacturing and high failure rates in clinical trials [7].

 

WHAT CAN BE DONE TO IMPROVE THE CLINICAL AND COMMERCIAL OUTCOME OF REGENERATIVE MEDICINE THERAPIES?

 

WHAT MAJOR DEVELOPMENTS IN REGENERATIVE MEDICINE WILL THE NEXT 10 YEARS BRING?

 

WHAT CAN THE GOVERNMENT, INDUSTRY AND ACADEMIA DO FOR THE UK TO STAY AT THE FOREFRONT OF REGENERATIVE MEDICINE?

 

 

 


Speakers

 


Programme

 


Registration

 


Sponsoring